EMEA-000780-PIP01-09-M06

Table of contents

Key facts

Invented name
Rydapt
Active substance
Midostaurin
Therapeutic area
Oncology
Decision number
P/0086/2021
PIP number
EMEA-000780-PIP01-09-M06
Pharmaceutical form(s)
  • Oral solution
  • Capsule, soft
Condition(s) / indication(s)
  • Treatment of acute myeloid leukaemia
  • Treatment of malignant mastocytosis
  • Treatment of mast cell leukaemia
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Ltd

Tel. +41 61 324 1111
E-mail: paediatric.enquiries@novartis.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating